Pyridine compounds as subtype selective modulators of alpha2B and/or alpha 2C adrenergic receptors

Details for Australian Patent Application No. 2010210513 (hide)

Owner Allergan, Inc.

Inventors Nguyen, Phong X.; Heidelbaugh, Todd M.; Sinha, Santosh C.; Chow, Ken; Garst, Michael E.; Gil, Daniel W.

Agent Davies Collison Cave

Pub. Number AU-A-2010210513

PCT Pub. Number WO2010/091209

Priority 61/152,398 13.02.09 US; 61/150,448 06.02.09 US

Filing date 4 February 2010

Wipo publication date 12 August 2010

International Classifications

C07D 401/06 (2006.01) Heterocyclic compounds containing two or more hetero rings

Event Publications

1 September 2011 PCT application entered the National Phase

  PCT publication WO2010/091209 Priority application(s): WO2010/091209

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010210521-Methods for controlling shipment of a temperature controlled material using a spill proof shipping container

2010210508-Multibranched bioadhesive compounds and synthetic methods therefor